ArticleThe AAPS journal2022

When to Extend Monitoring of Anti-drug Antibodies for High-risk Biotherapeutics in Clinical Trials: an Opinion from the European Immunogenicity Platform.

Gregor P Lotz et al.PubMed ↗Publisher ↗

No numbers read from the abstract.